![**Growth inhibitory effects of EGCG and SFN combinatorial treatment.**\
SH **(A)** and SHR **(B)** cells were treated with different concentrations of EGCG and SFN, alone or in combination for 3 days. Normal human mammary epithelial cells **(C)** were used as a control to test for potential toxicity. The circled combination of EGCG and SFN represented the optimal concentrations of these two compounds with physiological availability as well as potential synergistic effects on breast cancer growth inhibition. The treatment concentrations of EGCG or SFN alone or in combination are illustrated at the bottom of each graph. Columns, mean; bars, standard deviation.\
^†^p \< 0.001, significantly different from EGCG.\
^‡^p \< 0.001, significantly different from SFN.\
^§^p \< 0.05, significantly different from SFN.\
\*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001, significantly different from control.\
EGCG: Epigallocatechin-3-gallate; SFN: Sulforaphane; SH cells: Breast precancerous cells, derived from normal HMECs transfected with *SV40* and *hTERT*; SHR cells: Early transformed breast cancer cells, derived from normal HMECs transfected with *SV40, hTERT* and *H-Ras*.](epi-08-1019-g1){#F0001}

![**Apoptosis analysis by combined treatment with EGCG and SFN.**\
The concentrations of the combination treatment were 20 μM EGCG and 10 μM SFN based on synergistic effects of breast cancer growth inhibition as shown in [Figure 1](#F0001){ref-type="fig"}. Cellular apoptosis was detected by using an annexinV and PI staining system. **(A)** Becton Dickinson FACSCalibur Flow Cytometer was used to acquire and analyze a minimum of 105 events using the CellQuest program. The graphs are representative of three independent experiments. **(B)** Histogram of the apoptosis rate in SH (left panel) and SHR (right panel) cells in response to treatments with EGCG and SFN alone and combination. Columns, mean; bars, standard deviation.\
\*p \< 0.05; \*\* p \< 0.01 versus control.\
EGCG: Epigallocatechin-3-gallate; SFN: Sulforaphane; SH cells: Breast precancerous cells, derived from normal HMECs transfected with *SV40* and *hTERT*; SHR cells: Early transformed breast cancer cells, derived from normal HMECs transfected with *SV40, hTERT* and *H-Ras*.](epi-08-1019-g2){#F0002}

![**Effects of combinatorial treatment with EGCG and SFN on cell cycle distribution.**\
Precancerous SH cells **(A)** or early transformed breast cancer SHR cells **(B)** were treated with EGCG (20 μm) and SFN (10 μm), alone or in combination for 3 days followed by propidium iodide-based flow cytometric analysis. Bar charts reveal the percentage of cells in the indicated phases of the cell cycle in SH cells **(C)** and SHR cells **(D)**. The representative graphs are obtained from three independent experiments. Columns, mean; bars, standard deviation.\
^†^p \< 0.01, significantly different from EGCG.\
^‡^p \< 0.01, significantly different from SFN.\
\*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001, significantly different from control.\
EGCG: Epigallocatechin-3-gallate; SFN: Sulforaphane; SH cells: Breast precancerous cells, derived from normal HMECs transfected with *SV40* and *hTERT*; SHR cells: Early transformed breast cancer cells, derived from normal HMECs transfected with *SV40, hTERT* and *H-Ras*.](epi-08-1019-g3){#F0003}

![**Relative mRNA expression and enzymatic activities of HDAC1 and DNMT1 as well as global histone H3 acetylation level by EGCG and/or SFN treatment.**\
Precancerous SH cells and early transformed breast cancer SHR cells were treated with EGCG (20 μm) and SFN (10 μm), alone or combination. Quantitative real-time PCR was performed to measure relative transcription of *HDAC1* **(A)** and *DNMT1* **(B)**. Data were in triplicate from three independent experiments and were normalized to *GAPDH* and calibrated to untreated samples. **(C)** HDACs enzymatic activity; **(D)** DNMTs enzymatic activity. **(E)** Global histone H3 acetylation level. The values of enzymatic activities or acetylated histone H3 were derived from the means of three independent experiments. Columns, mean; bars, standard deviation.\
^†^p \< 0.01, significantly different from EGCG.\
^‡^p \< 0.01, significantly different from SFN.\
\*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001, significantly different from control.\
DNMT1: DNA methyltransferase 1; EGCG: Epigallocatechin-3-gallate; HDAC1: Histone deacetylases 1; SFN: Sulforaphane; SH cells: Breast precancerous cells, derived from normal HMECs transfected with *SV40* and *hTERT*; SHR cells: Early transformed breast cancer cells, derived from normal HMECs transfected with *SV40, hTERT* and *H-Ras*.](epi-08-1019-g4){#F0004}

![**Differential DNA methylation status in early transformed breast cancer SHR cells.**\
**(A)** Hierarchical clustering using BeadChip data cross four treatment groups (control, EGCG, SFN and combination) in SHR cells. A total of 266 selected probes were presented with absolute β difference greater than 0.2 compared with the control treatment. Each row represents a probe; each column represents a treatment. The level of DNA methylation (β value) is represented with a color scale as depicted above the heatmap. **(B)** Scatter plot illustrating distribution of methylation for selected genes ([Table 1](#T1){ref-type="table"}) with significant β changes in response to EGCG and SFN treatment. β values for different treatment groups are represented as the symbols with different colors and shapes as depicted in the legend. **(C)** Gene functional associations by gene ontology analysis by DAVID. Dotted line represents a threshold for p \< 0.05.\
EGCG: Epigallocatechin-3-gallate; SFN: Sulforaphane.](epi-08-1019-g5){#F0005}

![**Combinatorial treatment with EGCG and SFN caused expression changes in tumor-related genes through regulation of HDAC1 and DNMT1.**\
**(A)** and **(B)** q.uantitative real-time PCR was performed to measure relative transcription of *DCBLD2* **(A)** and *Septin 9* **(B)** in early transformed breast cancer SHR cells treated with EGCG (20 μm) and SFN (10 μm) alone or in combination. **(C & D)** Protein expression of DCBLD2 and Septin 9 in response to suppressed DNMT1 **(C)** or HDAC1 **(D)** Combination-treated or untreated SHR cells were transfected with either *DNMT1* siRNA (C) or *HDAC1* siRNA (D) to inhibit related gene expression and extracted protein after 3 days of transfection. **(E & F)** protein quantification for C **(E)** and D **(F)**. Data were in triplicate from three independent experiments and normalized to internal control and calibrated to levels in untreated samples. Columns, mean; bars, standard deviation.\
^†^p \< 0.01, significantly different from EGCG.\
^‡^p \< 0.01, significantly different from SFN.\
\*\*p \< 0.01; \*\*\*p \< 0.001, significantly different from control.\
DNMT1: DNA methyltransferase 1; EGCG: Epigallocatechin-3-gallate; HDAC1: Histone deacetylases 1; SFN: Sulforaphane.](epi-08-1019-g6){#F0006}

![**Inhibitory effects of GTPs and BSp diet on tumor growth of SHR breast cancer xenografts.**\
Female athymic nu/nu mice were injected with 2 × 10^6^ SHR cells and randomly separated to four groups (control, GTPs, BSp and combination group, see 'Materials and methods' section) with five mice in each group. Mice were administered either regular control diet, 0.5% GTPs in drinking water, 26% BSp diet or two diets in combination 2 weeks prior to injection and thereafter. **(A)** Tumor volume. Tumor volumes were observed weekly after injection and represented as mean values for each group. **(B)** Tumor weight. **(C)** Immunohistochemical analysis was performed in tumor samples to detect PCNA-positive cells for proliferation index (a, control; b, GTPs; c, BSp; d, combination group). Treatment with GTPs or BSp can cause local inflammation reaction and necrosis (see arrow point in b, c and d) in SHR breast xenografts. Representative photographs are from one field of each experimental group. **(D)** Bar chart is presented the immunohistochemical data in terms of percentage of PCNA-positive cells. PCNA-positive cells were counted in five different areas of the sections. Symbols and columns, mean; bars, standard deviation.\
^†^p \< 0.01, significantly different from BSp group.\
^‡^p \< 0.05, significantly different from GTPs group.\
\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, significantly different from control group.\
BSp: Broccoli sprout; GTP: Green tea polyphenol; PCNA: Proliferating cell nuclear antigen.](epi-08-1019-g7){#F0007}

Breast cancer is the most common cancer and the second leading cause of cancer death among women \[[@B1]\]. Although the precise mechanisms involved in breast tumorigenesis are still under intense investigation, it has been recently widely accepted that epigenetic aberration-induced gene expression changes play a major role in initiating breast carcinogenic processes \[[@B2]\]. Epigenetic mechanisms control gene expression via changing the accessibility of chromatin to transcriptional regulation locally and globally through modifications of the DNA and modification or rearrangement of nucleosomes \[[@B5]\]. Two major epigenetic mechanisms, DNA methylation and histone acetylation/methylation, are essential for organismal development and regulation of tissue-specific gene expression during normal physiological processes in mammals. However, disruption of epigenetic processes can lead to altered gene function and malignant cellular transformation \[[@B2],[@B5],[@B8]\]. It has become increasingly apparent that epigenetic alterations frequently occur in neoplastic cells involving abnormal epigenetic patterns in DNA methylation and histone modifications as well as dysregulation of epigenetic mechanisms. Therefore, global changes in the epigenetic landscape are a hallmark of cancer. Recently, numerous drugs that target epigenetic pathways have emerged and been widely tested in different clinical trials targeting various cancer types \[[@B9],[@B10]\]. However, high toxicity due to lack of specific targets in neoplastic cells as well as relatively low efficacy for solid tumors have largely limited epigenetic drugs applied in clinical practice for cancer therapy. Thus, exploration of less toxic, more attainable and effective natural compounds has been an emerging approach of epigenetic cancer therapy.

The 'epigenetic diets' refer to a small portion of bioactive diets with potent anticancer properties regulated via epigenetic events. Green tea polyphenols (GTPs) and broccoli sprouts (BSp) are two important epigenetic botanicals that have been extensively studied in our laboratory \[[@B11]\]. Epigallocatechin-3-gallate (EGCG) is a major polyphenol in green tea that has attracted intense interest. Studies have shown that green tea EGCG exhibits robust anticancer properties both *in vitro* and *in vivo* through regulation of multiple mechanisms including the induction of cell cycle arrest and apoptosis as well as inhibition of tumor metastasis and angiogenesis \[[@B16],[@B17]\]. Sulforaphane (SFN) is an isothiocyanate from cruciferous vegetables such as BSp and cabbage that has been well documented to reduce the risk of developing many common cancers through several mechanisms including cell cycle arrest, induction of apoptosis and Phase II detoxification enzymes \[[@B18],[@B19]\]. Interest in epigenetic regulation by EGCG and SFN in chemoprevention has recently surged due to their DNMTs and HDACs inhibition activities which lead to global and local alterations of DNA methylation and histone acetylation status of a number of tumor-related genes that may reverse tumor progression processes \[[@B20],[@B21]\]. Although our previous studies show potent effects of EGCG and SFN in preventing breast cancer when administered singly, it is important to test combinatorial effects of these two compounds that may overcome limitations of efficacy when acting alone and enhance safe and efficacious doses for consumption.

In the present study, we analyzed potential epigenetic mechanisms of combinatorial treatment with GTP/EGCG and BSp/SFN and their chemopreventive effects in a novel breast cancer cellular model, which resembles the processes of pathological progression and molecular events during earlier breast tumorigenesis. We observed that the combination of these botanicals resulted in a synergistic inhibition of cellular growth in precancerous breast cells and early breast cancer cells via, at least in part, regulating epigenetic mechanisms. This study will facilitate more effective uses of combinatorial epigenetic dietary approaches in breast cancer prevention and therapy.

Materials & methods {#S0001}
===================

Cell culture & cell treatment {#S0002}
-----------------------------

Normal human mammary epithelial cells (HMECs) were purchased from Lonza (Basel, Switzerland) at 15--20 population doublings. HMECs cells were stably transfected with either *SV40* and *hTERT* to obtain estrogen receptor (ER)-negative early transformed precancerous cells referred to SH cells, or additional oncogene *H-Ras* to obtain completely transformed breast cancer referred to SHR cells as done previously in our laboratory \[[@B22],[@B23]\]. HMECs cells were grown in serum-free mammary epithelial growth medium (MEGM) accompanied with MEGM SingleQuots (Lonza). Precancerous SH and early transformed breast cancer SHR cells were grown in Dulbecco\'s Modified Eagle Medium (Invitrogen, CA, USA) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA, USA) and 1% penicillin/streptomycin (Mediatech, VA, USA). Culture cells were maintained in a humidified environment of 5% CO~2~ and 95% air at 37°C and treated with indicted concentration of EGCG and/or SFN to evaluate the combinatorial effect of EGCG and SFN (Sigma, MO, USA) treatment. The culture medium was replaced every 24 h for the duration of the experiment.

MTT assay for cell viability {#S0003}
----------------------------

Aliquots of cells were seeded in triplicate in 96-well plates and treated with the indicated concentrations of EGCG and/or SFN to determine the effects of combinatorial treatment on cell viability. The MTT reagent (Sigma) was added to the culture medium followed by 4-h incubation at 37°C until purple precipitates are visible. The media were aspirated and the cells were dissolved in 100 μl DMSO. The absorbance of the cell lysates was measured at 570 nm by a microtiter plate reader (Bio-Rad, CA, USA) as done previously \[[@B23]\].

Cell apoptosis & cell cycle analysis {#S0004}
------------------------------------

Precancerous SH cells and early transformed breast cancer SHR cells treated with either EGCG at 20 μM or SFN at 10 μM alone or together were collected and washed with cold phosphate-buffered saline (PBS). Cellular apoptosis was analyzed by the Vybrant Apoptosis Assay kit \#2 (Invitrogen) as reported previously \[[@B23]\]. PI staining-based flow cytometry cell cycle assay was used to analyze cell cycle distribution. After washing with PBS, cells were fixed in 70% ethanol at -20°C overnight and washed with PBS twice. Cells were then suspended in PBS containing 0.1% Triton X-100, 0.1% RNase and 50 μg/ml PI and incubated in dark for about 30 min. Flow cytometry was used for both cell apoptosis and cell cycle analyses on a Becton Dickinson FACSCalibur Flow Cytometer. The fluorescence intensity of the viable cells was analyzed using CellQuest software.

Quantitative real-time PCR {#S0005}
--------------------------

Both precancerous SH and early transformed breast cancer SHR cells were cultured and treated as described above. Total RNAs from cells or mice tumor tissues were extracted using the RNeasy kit (Qiagen, CA, USA) according to the manufacturer\'s instructions and reversely transcribed to cDNA using iScript cDNA Synthesis kit (Biorad) as done previously \[[@B14],[@B23]\]. Gene expression were performed in triplicate and analyzed by real-time PCR using SYBR GreenER qPCR Supermix (Invitrogen) in a Roche LC480 thermocycler. Specific gene primers for *DNMT1, HDAC1, DCBLD2, Septin 9* and *GAPDH* were provided by Integrated DNA Technologies as following: 5′-ACCGCTTCTACTTCCTCGAGGCCTA-3′ (F), 5′-GTTGCAGTCCTCTGTGAACACTGTGG-3′ (R) for *DNMT1*; 5′-ATGGACGATCTGTTTCCCCT-3′ (F), 5′-CGGTTTACTCGGCAGATCTT-3′ (R) for *HDAC1*; 5′-GGGTAGTTTATGGATGTAAGGGT-3′ (F), 5′- CTGTTCCTCCTGCTCTTACTTG-3′ (R) for *DCBLD2*; 5′-CACAGCAAATGGGATCATCTC-3′ (F), 5′-CACTTCAAACAGCGGATCAC-3′ (R) for *Septin 9* and 5′-ACCACAGTCCATGCCATCAC-3′ (F) and 5′-TCCACCACCCTGTTGCTGTA-3′ (R) for *GAPDH*. Thermal cycling was initiated at 94°C for 4 min followed by 30 cycles of three steps of PCR amplification processes (94°C, 15 s; 60°C, 30 s) and melting curve analysis. *GAPDH* was used as an internal control and vehicle control was used as a calibrator. The relative changes of gene expression in fold change were calculated using the following formula: 2^-ΔΔCt^ = 2^-{ΔCt^ (treated samples) - ΔCt (control samples)}, where ΔCt = Ct (test gene) - Ct (GAPDH) and Ct represents threshold cycle number.

HDACs & DNMTs activity assay {#S0006}
----------------------------

Cultured cells were harvested at the indicated time points and nuclear proteins from SH and SHR cells were extracted. The activities of HDACs and DNMTs were evaluated by EpiQuik HDAC Activity/Inhibition Assay Kit and EpiQuik DNMT Activity/Inhibition Assay Kit (Epigentek, NY, USA) according to the manufacturer\'s protocols, respectively, as done previously \[[@B23]\].

Global histone H3 acetylation assay {#S0007}
-----------------------------------

Cultured SH and SHR cells were harvested by the indicated treatment of EGCG and/or SFN as described above. Histone protein was extracted and histone H3 acetylation level was detected according to the manufacturer\'s protocol of EpiQuik™ Global Histone H3 Acetylation Assay Kit (Epigentek). The histone H3 acetylation level was detected by using a microplate reader at 450 nm.

Genome-wide DNA methylation analysis {#S0008}
------------------------------------

Early transformed breast cancer SHR cells were cultured and treated as described above. Total DNA from SHR cells were extracted and converted using the EpiTect Bisulfite Kits (Qiagen) according to manufacturer instructions. Genome-wide DNA methylation status was measured at 485,577 CpG islands using Illumina\'s Infinium HumanMethylation450 BeadChip \[[@B24]\]. Illumina\'s GenomeStudio^®^ methylation module was used to calculate the methylation level at each CpG island as the beta-value (β = intensity of the methylated allele \[M\]/\[intensity of the unmethylated allele (U) + intensity of the methylated allele (M) + 100\]). Bioconductor package minfi was used to process and analyze the BeadChip data. The data were normalized using the SWAN (subset-quantile within array normalization) method to reduce the variability between the two types of probes. Beta-values were then transformed to obtain the log ratio, defined as log(β/\[1-β\]) to compare between the treatments.

Western blot analysis {#S0009}
---------------------

Cultured SH and SHR cells were treated by the indicated treatments of EGCG and/or SFN and total proteins from the cells were extracted by RIPA Lysis Buffer (Upstate Biotechnology, VA, USA). Proteins were electrophoresed in Biorad SDS-polyacrylamide ready gels and transferred onto nitrocellulose membranes. Membranes were then probed with different antibodies to DCBLD2 (Thermo Scientific, Waltham, MA, USA), Septin 9 (Thermo Scientific, Pierce), HDAC1 (H11; Santa Cruz Biotechnology) and DNMT1 (ab 13537; Abcam, CA, USA) respectively, and each membrane was stripped and reprobed with beta-actin antibody (13E5, Cell Signaling Technology, MA, USA) as loading control. Immunoreactive bands were visualized using the enhanced chemiluminescence detection system (Santa Cruz Biotechnology) and documented by a ChemiDoc™ Imaging Systems (Biorad).

RNA interference {#S0010}
----------------

Validated siRNA for *DNMT1* (ID: S4215) and *HDAC1* (ID: S73) and the positive/negative control RNAi (Thermo Scientific, Applied Biosystems) were transfected into early transformed SHR cells by indicated treatment using the Silencer siRNA Transfection II Kit (Thermo Scientific) according to the protocols provided by the manufacturer \[[@B23]\].

Animal models, dietary & experimental designs {#S0011}
---------------------------------------------

An orthotopic breast cancer mouse model was used in this study. Virgin female immunodeficiency Nu/Nu Nude mice (Crl:NU-*Foxn1nu*) at 4--6 weeks of age were obtained from Charles River Laboratories (Wilmington, MA, USA) and housed in the Animal Resource Facility of the University of Alabama at Birmingham (UAB) under the following conditions: 12-h dark/12-h light cycle, 24 ± 2°C temperatures and 50 ± 10% humidity. An online power calculator \[[@B25]\] was used to calculate the power/sample size by two-proportion comparison based on our *in vitro* data. A sample size of five mice/group will give us 75% power for detecting beneficial botanical effects for a one-sided test at significance level of 0.05 (α = 0.05).

After 1 week of acclimatization, Nu/Nu Nude mice were randomly divided into four experimental groups (five mice each): control group: mice were fed with AIN-93G diet; GTPs diet: 0.5% (5 mg/ml) of GTPs (Sunphenon 90D, Taiyo International, Inc., MN, USA) were administered in drinking water; BSp diet: mice were fed with 26% of BSp diet (modified AIN-93G diet supplemented with 26% BSp seeds; TestDiet, MO, USA); combination diet: mice were fed with both GTPs and BSp diets. Mice were administered the corresponding experimental diets from 2 weeks prior to injection throughout the study. A 100 μl of exponentially growing breast cancer SHR cells (2 × 10^6^) was injected orthotopically into the second or third pair of the right thoracic mammary fat pad of each mouse to determine the *in vivo* efficacy of these diets on human breast tumor development.

Tumor sizes and body weight were measured weekly. Tumor volumes were calculated using the formula: tumor volume (cm^3^) = (length × width^2^) × 0.523 \[[@B23]\]. Tumor volume on day 1 (injection day) is considered as 1. The experiment was terminated when the mean of tumor diameter in the control mice exceeded 1.0 cm following the guidelines of Institutional Animal Care and Use Committee at UAB. At the end of the experiment, the primary breast tumors were excised, weighed and appropriately stored for further analysis. Animal procedures were reviewed and approved by UAB Institutional Animal Care and Use Committee (Animal Project Number: 110109327).

Immunohistochemical determination of tumor cell proliferation {#S0012}
-------------------------------------------------------------

Primary breast tumor tissues were dissected and fixed in 10% buffer-neutralized formalin for histology and immunohistochemistry. Tumor slices (5 μm thick) were deparaffinized and rehydrated in a series of graded alcohols. Antigens were retrieved in boiling 10 mmol/l sodium citrate buffer (pH 6.0) for 20 min. The slides were then washed in PBS and blocked with 1% bovine serum albumin. After blocking, the slides were incubated with antiproliferating cell nuclear antigen (PCNA; Cell Signaling Technology) for 2 h at room temperature. After washing in PBS, the sections were incubated with biotinylated secondary antibody for 45 min followed by horseradish peroxidase-conjugated streptavidin, incubated with diaminobenzidine substrate and counterstained with hematoxylin. Representative photographs were taken and the numbers of PCNA-positive cells were detected and counted by a licensed pathologist. Microscopic immunohistochemical analysis of breast tissue sections was performed using an Olympus BX41 microscope fitted with a Q-color 5 Olympus camera.

Statistical analyses {#S0013}
--------------------

Statistical significance between treatment and control groups was evaluated by one-way ANOVA followed by Tukey\'s test for multiple comparisons by using GraphPad Prism 5.00 version. Values were presented as mean ± SD and p \< 0.05 was considered significant. Western-blot protein density was analyzed by Image J software developed by NIH.

Results {#S0014}
=======

EGCG & SFN in combination significantly inhibited initiation of breast tumorigenesis {#S0015}
------------------------------------------------------------------------------------

To elucidate the combinatorial efficacy of the GTP EGCG and BSp SFN on cellular viability, we used a well-established cellular cancer transformation system that closely mimics the process of early human breast tumorigenesis. In this model, three defined genetic elements including *SV40, hTERT* and *H-Ras* were introduced into normal HMECs to undergo a neoplastic transformation \[[@B26],[@B27]\]. During this process, different stages of human mammary cancer cells were generated to represent cellular malignant progression during early breast carcinogenesis including breast precancerous cells (SH cells, transfected with *SV40* and *hTERT*) and early transformed breast cancer cells (SHR cells, transfected with all three genetic elements) \[[@B23]\]. This system has been verified and successfully used in breast cancer research as a useful prevention as well as therapeutic *in vitro* model system \[[@B22]\]. Precancerous SH cells and early transformed breast cancer SHR cells were established in our laboratory at around 20 population doublings when experiments were initiated as reported previously \[[@B23]\].

We initiated our study to determine the optimal dose of combined EGCG and SFN treatment that will induce synergistic cellular growth inhibition in precancerous SH and early transformed breast cancer SHR cells without causing toxicity to normal breast epithelial cells. The MTT assay was performed with SH and SHR cells treated with various concentrations of EGCG and SFN as shown in [Figure 1](#F0001){ref-type="fig"}A & B. The maximal treatment concentrations are 40 μM for EGCG and 20 μM for SFN based on practicable consumable doses of these diets and our previous findings in other breast cancer cell lines \[[@B14],[@B15]\]. We found that SFN treatment alone significantly inhibited cellular growth in precancerous SH cells and early transformed breast cancer SHR cells in a dose-dependent manner, whereas EGCG treatment alone can only affect cellular growth at the highest treatment concentration both in SH and SHR cells ([Figure 1](#F0001){ref-type="fig"}A & B). Strikingly, all combination treatments induced significant cellular growth inhibition compared with control, EGCG and SFN alone, suggesting that combinatorial treatment with GTPs and BSp are more efficacious in suppressing breast cancer initiation than any of these two compounds acting alone and that a potential synergistic inhibitory effect is induced. We finally chose optimal combinatorial treatment concentrations of 20 μM EGCG and 10 μM SFN in both precancerous SH and early transformed breast cancer SHR for our subsequent studies due to the relatively low concentrations for each treatment and the more effective tumor inhibitory rate by this combinatorial regimen. Furthermore, this optimal combinatorial treatment concentration exhibits a synergistic effect on inhibiting cell proliferation in both precancerous SH (Combination Index \[CI\] = 0.56) and early transformed breast cancer SHR (CI = 0.53) as determined by an online software, CompuSyn software, in which CI \<1, = 1 and \>1 indicate synergism, additive effect and antagonism, respectively \[[@B28]\].

We also evaluated the potential toxicity of this combination in normal breast HMECs ([Figure 1](#F0001){ref-type="fig"}C) and found that the tested concentrations of EGCG and SFN did not cause inhibitory effects on cell viability in HMECs indicating this treatment is likely safe. This dietary combination regimen using relatively low concentrations of EGCG and SFN is physiologically accessible and practical for humans as it represents only 74--148 ml/dose of 0.5% GTPs or 12--23 g BSp/serving consumed per day by an adult human \[[@B29],[@B30]\]. Based on these results, we therefore chose to use 20 μM EGCG and 10 μM SFN as optimal combined concentrations in our subsequent studies.

Combined treatment with EGCG & SFN induced cellular apoptosis in early transformed breast cancer SHR cells {#S0016}
----------------------------------------------------------------------------------------------------------

To address how combined treatment with EGCG and SFN affects cellular proliferation, we conducted cell apoptosis assays on precancerous SH cells and early transformed breast cancer SHR cells with the aforementioned treatments. As indicated in [Figure 2](#F0002){ref-type="fig"}A & B (right panel), we found that either EGCG or SFN treatment alone or in combination resulted in significant apoptosis in breast cancer SHR cells (p \< 0.05), but combination treatment induced a more prominent apoptosis compared with control cells (p \< 0.01) with a synergistic effect (CI = 0.05). However, these treatments did not induce significant cellular apoptosis in precancerous SH cells as shown in [Figure 2](#F0002){ref-type="fig"}A & B (left panel). In addition, the optimal combined treatment did not cause a dramatic increase in apoptosis rate (\<20%) indicating less toxicity and more safe practical potential. Consistent with the results of cell viability shown in [Figure 1](#F0001){ref-type="fig"}, we speculated that this dietary regimen may exhibit greater efficacy in inducing cellular growth inhibition and apoptosis in early transformed SHR cells than pre-transformed SH cells, indicating its potent chemotherapeutic and chemopreventive potential against breast tumorigenic cells.

Combinatorial treatment with EGCG & SFN induced cell cycle arrest {#S0017}
-----------------------------------------------------------------

To further investigate the effects of this dietary combination regimen on the cell cycle, the cell cycle profiles of precancerous SH cells and early transformed breast cancer SHR cells were analyzed using flow cytometry. We found EGCG and SFN treatment resulted in a significant increase in the percentage of cells in the S-phase in precancerous SH cells (p \< 0.001; [Figure 3](#F0003){ref-type="fig"}A & C), whereas it led to significantly cell accumulation in both S- (p \< 0.001) and G2/M-phase (p \< 0.01) in breast cancer SHR cells ([Figure 3](#F0003){ref-type="fig"}B & D). Compared with EGCG treatment alone, SFN treatment alone is more effective in inducing cell cycle arrest indicating SFN may play a dominating role on suppressing breast cancer development in this combination regimen. These results suggest that combinatorial dietary regimen of EGCG and SFN mediates cell growth inhibition by inducing cell cycle arrest, especially in completed transformed breast cancer cells.

Epigenetic enzymatic expression & activity changes in response to EGCG & SFN treatments {#S0018}
---------------------------------------------------------------------------------------

To further interpret the mechanisms of epigenetic modulations by EGCG and/or SFN treatment during breast tumorigenesis, we assessed gene expression and enzymatic activities of two important epigenetic-associated enzymes involved in regulation of histone acetylation and DNA methylation such as HDACs and DNMTs, respectively. As shown in [Figure 4](#F0004){ref-type="fig"}A--D, right panels, EGCG and SFN treatment significantly reduced gene expressions and enzymatic activities of both HDAC1 and DNMT1 in early transformed SHR cells, suggesting that this dietary combination treatment may exert its antibreast cancer properties through, at least in part, regulation of epigenetic pathways. The combinatorial treatment was more effective in inhibiting gene expressions and enzymatic activities of HDAC1 and DNMT1 compared with control, EGCG and SFN treatment alone. In addition, we found EGCG and SFN in combination can only induce significant changes of these epigenetic modulators in early transformed breast cancer SHR cells ([Figure 4](#F0004){ref-type="fig"}A--D, right panels) but not in precancerous SH cells ([Figure 4](#F0004){ref-type="fig"}A--D, left panels), which is consistent with our abovementioned findings that this dietary regimen is more effective on early transformed breast cancer cells. Unlike the transformed breast cancer SHR cells, the expressions of *HDAC1* and *DNMT1* in precancerous SH cells are not matched by the relevant enzymatic activities suggesting a different epigenetic regulatory mechanism may be involved in these two cells during early breast cancer initiation.

Although there is no synergistic effect found in the activities of DNMT1 and HDAC1 in transformed breast cancer SHR cells ([Figure 4](#F0004){ref-type="fig"}C & D, right panels), we found an additive effect (CI = 1) in expression of *HDAC1* ([Figure 4](#F0004){ref-type="fig"}A, right panel) and a synergistic effect (CI = 0.67) in *DNMT1* expression ([Figure 4](#F0004){ref-type="fig"}B, right panel) in response to combined treatment with EGCG and SFN. Based on our previous studies, EGCG is a strong inhibitor for DNMTs but has relative weak inhibitory effects on HDACs \[[@B14],[@B20]\], whereas SFN has shown a strong inhibitory effect on HDACs \[[@B15],[@B21]\]. In [Figure 4](#F0004){ref-type="fig"}A & C, right panels, both EGCG and SFN treatment alone significantly reduced HDAC1 expressions and enzymatic activities in SHR cells because both of these compounds are HDACs inhibitors, and combination leads to a further reduction. However, SFN treatment alone cannot induce significant changes in DNMT1 expression and enzymatic activity ([Figure 4](#F0004){ref-type="fig"}B & D, right panels) due to its limited impact on DNMTs. This inhibitory effect is strengthened when SFN is combined with EGCG indicating an interaction between these two compounds may act in regulation of epigenetic pathways. These results indicate that EGCG and SFN treatment may affect epigenetic pathways most likely via influencing histone acetylation and DNA methylation leading to a reversal of aberrant epigenetic profiles during early breast tumorigenesis and cancer suppression.

EGCG & SFN in combination increased global histone H3 acetylation level {#S0019}
-----------------------------------------------------------------------

Although we observed significant changes in epigenetic modulators by dietary EGCG and SFN treatments ([Figure 4](#F0004){ref-type="fig"}A--D), we next sought to investigate further epigenetic mechanisms regulated by this combinatorial treatment during breast tumorigenesis. We evaluated global histone acetylation level by measuring global acetylation of histone H3, which is the most common acetyl-modified histone. As shown in [Figure 4](#F0004){ref-type="fig"}E, combined treatment with EGCG and SFN significantly increased global acetylation of histone H3 in both precancerous SH cells and early transformed breast cancer SHR cells, and this increment is more obvious in SHR cells (p \< 0.001, significantly different from control, EGCG and SFN) than in SH cell (p \< 0.01, significantly different from control), which is consistent with our previous results that this dietary regimen is more effective on breast cancer cells. This result suggests that our novel dietary combination regimen results in an open chromatin structure leading to an alteration of global gene expression profile that may contribute to its antibreast cancer properties through, at least in part, repression of HDAC1 expression and/or activity.

Genome-wide DNA methylation alterations in response to EGCG & SFN treatment {#S0020}
---------------------------------------------------------------------------

We further extended our study by testing genome-wide DNA methylation alterations in early transformed breast cancer SHR cells in response to EGCG and/or SFN treatment. To investigate methylation status between different treatment groups, hierarchical clustering was conducted on 266 selected probes for all single and combined treatments with absolute β difference greater than 0.2 compared with the control treatment ([Figure 5](#F0005){ref-type="fig"}A). Among them, 51 probes in combination are hypermethylated and 44 are hypomethylated. The clusters showed significant variation of DNA methylation status between control, EGCG, SFN and combination groups suggesting epigenetic mechanisms may play a role in dietary EGCG and SFN-associated breast cancer preventive and therapeutic effects. Functional gene ontology analysis ([Figure 5](#F0005){ref-type="fig"}C) indicates multiple cellular pathways have been modulated, such as chromosomal structure, RNA binding and differentiation, that may eventually contribute to breast cancer prevention effects by this combinatorial dietary treatment. To identify individual gene loci whose methylation status were correlated with EGCG and SFN treatment-induced breast cancer inhibition, we selected 21 genes with significant β changes in response to EGCG and SFN treatment which also have been documented to be associated with cancer development and controlled by epigenetic factors ([Figure 5](#F0005){ref-type="fig"}B) \[[@B31]\]. As illustrated in [Table 1](#T1){ref-type="table"}, we observed that EGCG and SFN treatment induced DNA methylation alterations on several genes that may correlate with this dietary regimen-induced breast carcinogenesis suppression. In addition, we discovered a greater change of DNA methylation status in these tumor-related genes by the combination treatment with EGCG and SFN than any of these two compounds acting alone. Collectively, these results suggest that combinatorial treatment with EGCG and SFN can affect epigenetic markers of key tumor-related genes leading to inhibition of breast tumor initiation and development.

Combinatorial treatment with EGCG & SFN caused expression changes in tumor-related genes due to regulation of epigenetic pathways {#S0021}
---------------------------------------------------------------------------------------------------------------------------------

To further verify the correlation of DNA methylation status with actual gene expression, we evaluated expression of selected tumor-related genes in which the DNA methylation status are significantly altered by the treatment of EGCG and SFN as shown in [Figure 5](#F0005){ref-type="fig"} & [Table 1](#T1){ref-type="table"}. Two important tumor-related genes were chosen to represent tumor suppressor gene such as *DCBLD2* \[[@B51]\] and tumor promoting gene such as *SPET9* (*Septin 9*) \[[@B38],[@B39]\]. We found that EGCG and SFN treatment alone and in combination significantly upregulated tumor suppressor gene *DCBLD2* ([Figure 6](#F0006){ref-type="fig"}A) but downregulated tumor promoting gene *Septin 9* ([Figure 6](#F0006){ref-type="fig"}B) in early transformed breast cancer SHR cells. These gene expression changes are positively associated with their DNA methylation status alterations suggesting epigenetic mechanisms may be involved in dietary EGCG and SFN-induced breast cancer suppression. We extended our experiment to further illustrate potential epigenetic mechanisms linking this novel combination treatment to its inhibitory effects on early breast cancer initiation. We found that combinatorial treatment-induced protein expression in DCBLD2 and Septin 9 was consistent with mRNA expression as shown [Figure 6](#F0006){ref-type="fig"}A & B. DNMT1 and HDAC1 knockout studies showed upregulation of DCBLD2 and Septin 9 protein expression ([Figure 6](#F0006){ref-type="fig"}C--F). However, combinatorial treatment with EGCG and SFN significantly reinforced protein increment of the tumor suppressor gene, DCBLD2, when two epigenetic modulators, DNMT1 ([Figure 6](#F0006){ref-type="fig"}C & E) and HDAC1 ([Figure 6](#F0006){ref-type="fig"}D & F), are suppressed. On the contrary, EGCG and SFN treatment attenuates the activation effects of repressed DNMT1 and HDAC1 on protein expression of the tumor promoting gene, Septin 9. These results further indicate that combined GTPs/EGCG and BSp/SFN are highly effective in inhibiting early breast cancer development by, at least in part, regulating epigenetic mechanisms.

Dietary GTPs & BSp inhibited the growth of breast cancer xenografts {#S0022}
-------------------------------------------------------------------

To determine the *in vivo* breast cancer inhibitory properties of dietary GTPs and BSp, we conducted animal experiments to examine whether dietary administration of either GTPs and BSp alone or in combination can inhibit the growth of breast cancer xenografts. We used early transformed breast cancer cells, SHR, to grow xenografts in athymic nude mice that had been fed 0.5% GTPs in drinking water and/or a diet supplemented with 26% BSp for two weeks before injection of the tumor cells and the treatment continued throughout the study. The concentrations of the diets used in this study are converted from our *in vitro* study. They are considered physiologically available and correspond to drinking 2--3 cups (2.5 mg EGCG/ml water) of green tea and consuming 266 g (∼4 cups) BSp/per day by an adult human, respectively \[[@B55],[@B56]\].

Periodic measurement of the tumor volume indicated that both dietary GTPs and BSp significantly suppressed tumor growth from as early as 3 week post injection. However, combinatorial treatment of GTPs and BSp was significantly more efficacious in inhibiting breast xenograft growth throughout the experimental time frame with an overall 93.87% inhibition rate compared with 74.89% for GTPs alone and 58.22% for BSp alone ([Figure 7](#F0007){ref-type="fig"}A & [Table 2](#T2){ref-type="table"}). It also indicates that combined GTPs and BSp lead to a synergistic effect on tumor inhibition (CI = 0.167). The wet weight of the SHR xenograft tumors per mouse was significantly lower in the mice administered either GTPs or BSp diet, especially GTPs and BSp in combination, as compared with the mice that received the control diet ([Figure 7](#F0007){ref-type="fig"}B). Although combined treatment with GTPs and BSp showed a striking effect of repression of breast tumor growth (inhibition rate 93.87%), the ability of this combinatorial treatment on inhibiting of breast cancer initiation is the same as GTPs treatment alone (prevention rate 60%) as interpreted in [Table 2](#T2){ref-type="table"}, indicating this dietary regimen is more efficacious in inhibiting early transformed breast cancer than precancerous breast lesions.

To further analyze the potential *in vivo* antiproliferative properties of dietary GTPs and BSp administration, we performed immunohistochemical assays to detect PCNA-positive cells as an *in vivo* indicator for cellular proliferation in mice SHR xenograft tumors. As shown in [Figure 7](#F0007){ref-type="fig"}C & D, PCNA-positive cells that represent proliferating cells in mice xenograft tumors were significantly depleted by GTPs and BSp treatment alone (p \< 0.05) and the percentage of PCNA-positive cells were significantly reduced by 26.74-fold in breast tumors of the combination group compared with the control group (p \< 0.01). In addition, combinatorial treatment with GTPs and BSp further significantly inhibited PCNA expression (p \< 0.01) than the other single-treatment groups suggesting this combinatorial region induced a synergistic effect of cellular proliferation inhibition *in vivo*. This result indicates that dietary GTPs and BSp can inhibit breast tumor growth in an *in vivo* system by affecting the proliferation rate of xenograft tumor growth.

Discussion {#S0023}
==========

The intriguing effects of the bioactive botanic components on cancer chemoprevention and therapy have recently received considerable attention due to their characteristics of safe use, physiological availability and robust control on multiple signal pathways that affect carcinogenesis. GTP EGCG and BSp SFN are among the most important bioactive dietary compounds that have potent anticancer properties \[[@B11]\]. Although various molecular mechanisms have been proposed involving EGCG- or SFN-induced inhibitory effects on many types of cancers such as induction of apoptosis and cell cycle arrest, another important mechanism modulated by EGCG and SFN pertains to influencing epigenetic pathways leading to correction of aberrant epigenetic marks in cancer cells \[[@B16]\]. Our previous studies and others have found that GTP EGCG can influence epigenetic pathway via direct and/or indirect inhibition of DNMTs activity, thereby leading to beneficial reversals of aberrant DNA methylation profiles of multiple tumor-related genes \[[@B14],[@B20]\]. BSp SFN in cancer chemoprevention has recently surged due to its HDACs inhibition activity which leads to an increase in the global and local histone acetylation of a number of genes \[[@B15],[@B21]\]. Although the mechanisms involved in EGCG- or SFN-induced anticancer properties have been intensively investigated, relatively few studies have focused on the combined potential of nutritive components and their epigenetic mechanisms. These botanicals have similar favorable biological effects on epigenetic regulation but different mechanisms for carrying out these effects. For example, EGCG acts as a DNMTs inhibitor reducing the aberrant gene hypermethylation and SFN is an HDACs inhibitor that can remodel chromatin structure by affecting histone acetylation status in cancer cells. Both compounds are effective when acting alone in preventing breast cancer *in vitro* and *in vivo* and their combined effects may be synergistic.

We therefore tested our hypothesis *in vitro* and *in vivo* to better understand the potential combinatorial effects of GTP EGCG and BSp SFN during early breast tumorigenesis, and more importantly, to explore the preventive or therapeutic properties of this combination and potential molecular mechanisms in reversing breast malignancy. We started our work on an established cancer chemoprevention model that causes normal breast cells to undergo cancer initiation. This cellular model system resembles both pathological progression as well as potential molecular events in early breast oncogenic transformation through sequential oncogenic transfection to normal human epithelial cells \[[@B26],[@B27]\]. Although this is an artificial cellular system and the individual genetic mutations and subsequent alterations of signal pathways may not occur in all types of breast cancer, this model has been well documented to study potential molecular mechanisms during early breast tumorigenesis not only because it closely approximates the initiation and early progression of breast cancer, it also very easy to manipulate as stable transfected cell lines such as precancerous SH cells and transformed breast cancer SHR cells that represent different stages of breast cancer are available \[[@B22]\]. This model therefore enables us to assess the impact of the botanical combinatorial regimen in real-time not only in preventing the transition to oncogenesis, but also in preventing the epigenetic aberrations that are frequently associated with breast cancer. Such studies will help to elucidate the potential of applying this novel botanical combination in future clinical trials.

In the present study, our results showed a synergistic effect on inhibition of breast cancer growth when EGCG and SFN were used together at relatively low concentrations of 20 μM EGCG and 10 μM SFN without causing toxicity in normal control breast HMECs. This result indicates that the combinatorial botanical approach is more efficacious than when these botanicals are used singly and that this combination is safe. The dietary combinatorial regimen using relatively low concentrations of EGCG and SFN is physiologically accessible by daily consumption of GTPs and BSp, which are equal to drinking 2--3 cups of green tea and consuming 266 g (∼4 cups) BSp/per day by an adult human, respectively \[[@B14],[@B15],[@B55],[@B56]\]. Thus it has an important bioavailability toward chemoprevention and therapy against breast cancer. Importantly, the combined use of GTPs and SFN in breast cancer prevention and therapy could potentially allow lower levels of consumption with no toxicity, which is crucial to overcome many of the barriers of combinatorial chemoprevention while significantly advancing the use of these dietary components.

This combination also induced significant cellular apoptosis and cell cycle arrest in S- and G2/M-phases in early transformed breast cancer SHR cells. Interestingly, we found that EGCG and SFN administration induced more significant effects on cellular viability inhibition, apoptotic response and cell cycle arrest in early transformed breast cancer SHR cells rather than precancerous SH cells. These results suggest that this dietary combination regimen may predominately employ its anticancer effect at early stages of breast tumorigenesis, indicating important chemotherapeutic and chemoprevention effects of this dietary regimen on inhibiting early breast progression that may apply in future clinical trials.

Further mechanistic studies revealed that the combinatorial treatment with EGCG and SFN may influence epigenetic pathways via inducing alterations of gene expression and enzymatic activities of DNMT1 and HDAC1 in early transformed breast cancer. Aberrant epigenetic modifications frequently occur during breast tumorigenesis. For example, aberrant DNA methylation status and abnormal histone modification profiles may lead to perturbations of chromatin structure, dysregulation of gene expression and genomic instability, that contribute to early cellular transformation and malignant initiation \[[@B1]\]. This abnormities are more prevalent in early transforming tumor cells, which could explain the phenomenon we found in our study that combined treatment with EGCG and SFN are more efficacious in early transformed breast SHR cells. Genome-wide methylation analysis showed differential DNA methylation status changes in multiple tumor-related genes in early transformed breast cancer cells in response to this combinatorial regimen. In addition, combination treatment with EGCG and SFN also significantly increased global acetylation level of histone H3. These results suggest that these dietary compounds may exert their anticancer effects primarily through reversing aberrant epigenetic codes during early breast tumorigenesis. Besides EGCG in green tea and SFN in broccoli sprouts, there are many epigenetic diets such as genistein in soybean and resveratrol in berries that have been identified to frequently regulate key tumor-related gene expression including *ERα, hTERT* and *p16^INK4a^* via epigenetic mechanisms leading to various cancer chemoprevention effects \[[@B14],[@B15],[@B23],[@B58],[@B59]\]. Further results indicate causal effects of DNMT1 and HDAC1 gene expressions and/or enzymatic enzymatic activities on regulation of key tumor-related genes suggesting epigenetic mechanisms play a major role in this novel dietary combinatorial regimen-induced chemoprevention and therapeutic effect on early breast cancer.

We also tested this dietary regimen in a mouse xenograft system. Consistently, orally fed GTPs and BSp diets significantly inhibited tumor growth of breast cancer xenografts than any of these two diets acting alone. The bioavailability of EGCG is considered high compared with other tea catechins since a large proportion of EGCG in plasma is in a free form \[[@B55]\]. Studies also show that SFN is rapidly absorbed and displayed an absolute bioavailability of 82% in a dose-dependent pharmacokinetic behavior \[[@B60]\]. Thus, this combinatorial dietary regimen can achieve physiologically relevant bioavailability and practical consumption levels *in vivo*. Practically, this can also be achieved by consuming concentrated BSp/SFN supplement for future clinical trial. Collectively, these studies indicate that combined GTPs and BSp are highly effective in inhibiting early breast cancer development by, at least in part, regulating epigenetic mechanisms.

Conclusion {#S0024}
==========

In summary, our findings provide important observations for the use of safe and effective combinations of epigenetic botanical compounds including GTP EGCG and BSp SFN to reverse epigenetic aberrations in early breast cancer. This novel dietary combinatorial regimen has high translational potential by providing lower doses of these compounds, increased practicality and compliance, reduced toxicity risk as well as enhanced efficacy and greater cost effectiveness in breast cancer management. Future efforts aimed at determining the appropriate administration of these combined botanicals in breast cancer patients and elucidating the further anticancer mechanisms are needed.

###### **Selected tumor- or epigenetic-related genes with significant β changes in response to epigallocatechin-3-gallate and sulforaphane treatment.**

  **UCSC ref gene name**   **Gene full name**                                            **Methylation status change**   **Gene function**                                                                                                                     **Ref.**
  ------------------------ ------------------------------------------------------------- ------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- -------------------
  ^ω^*MAML2*               Mastermind-like 2                                             Hypermethylation                Promote tumor growth                                                                                                                  \[[@B31]\]
  ^λ^*PON1*                Paraoxonase 1                                                 Hypermethylation                Multifactorial antioxidant enzyme paraoxonase family; SNP variation is related to breast cancer; methylation regulation is involved   \[[@B32]\]
  ^ω^*PBX1*                Pre-B-cell leukemia homeobox 1                                Hypermethylation                Relevant to ER-positive breast cancer progression; regulated by epigenetic factors                                                    \[[@B33],[@B34]\]
  ^ξ^*MAGED1*              Melanoma antigen family D, 1                                  Hypermethylation                Inhibit tumor growth; regulated by epigenetic mechanisms                                                                              \[[@B35]\]
  ^ε^*SLCO3A1*             Solute carrier organic anion transporter family, member 3A1   Hypermethylation                Breast cancer regulated gene; regulated by epigenetic mechanisms                                                                      \[[@B36]\]
  ^ξω^*CCKBR*              Cholecystokinin B receptor                                    Hypermethylation                Promote breast cancer; regulated by epigenetic factors                                                                                \[[@B37]\]
  ^λ^*SEPT9*               Septin 9                                                      Hypermethylation                Tumor-related gene, regulated by epigenetic mechanisms                                                                                \[[@B38],[@B39]\]
  ^\#^*GRB10*              Growth factor receptor-bound protein 10                       Hypermethylation                Tumor-related gene, regulated by epigenetic mechanisms                                                                                \[[@B40]\]
  ^δ^*IPO7*                Importin 7                                                    Hypermethylation                Tumor-related gene, regulated by epigenetic mechanisms                                                                                \[[@B41],[@B42]\]
  ^λ^*CCNY*                Cyclin Y                                                      Hypermethylation                Tumor promoting gene                                                                                                                  \[[@B43]\]
  ^λ^*EPHB1*               EPH receptor B1                                               Hypermethylation                Loss of expression in gastric carcinoma associated with invasion and metastasis                                                       \[[@B44]\]
  ^\#^*RDH10*              Retinol dehydrogenase 10                                      Hypermethylation                Tumor-related gene, regulated by epigenetic mechanisms                                                                                \[[@B45]\]
  ^\*^*PSMA7*              Proteasome subunit, alpha type, 7                             Hypomethylation                 Tumor suppressor gene                                                                                                                 \[[@B46]\]
  ^ω^*PRKCA*               Protein kinase C, alpha                                       Hypomethylation                 Breast tumor related gene                                                                                                             \[[@B47]\]
  ^\#^*MIR196B*            MicroRNA 196b                                                 Hypomethylation                 Oncogene                                                                                                                              \[[@B48]\]
  ^\*^*TMEM198*            Transmembrane protein 198                                     Hypomethylation                 Related with Wnt pathway                                                                                                              \[[@B49]\]
  ^ω^*ALCAM CD166*         Activated leukocyte cell adhesion molecule CD166              Hypomethylation                 Strong relevance to breast cancer                                                                                                     \[[@B50]\]
  ^\#^*DCBLD2*             Discoidin, CUB and LCCL domain containing 2                   Hypomethylation                 Tumor suppressor gene, regulated by epigenetic mechanisms                                                                             \[[@B51]\]
  ^ε^*MSI2*                Musashi RNA-binding protein 2                                 Hypomethylation                 Tumor-related genes                                                                                                                   \[[@B52]\]
  ^\#^*RPS19*              Ribosomal protein S19                                         Hypomethylation                 Tumor-related genes                                                                                                                   \[[@B53]\]
  ^λ^*TRMT12*              Trna methyltransferase 12 homolog                             Hypomethylation                 Overexpression in breast cancer                                                                                                       \[[@B54]\]

Probe location in the gene: ^\*^N-Shelf, ^ξ^N-Shore, ^δ^S-Shelf, ^ε^S-shore, ^\#^CpG island, ^ω^Enhancer and ^λ^Others.

###### **Combined treatment with green tea polyphenol and broccoli sprout inhibited tumor growth in mouse SHR xenografts.**

  **Animal group**   **Diet and treatment**                                   **Prevention rate^†^ (%)**   **TV^‡^ mm^3^ (mean ± SD)**   **RTV^§^ (mean)**   **IR^¶^ (%)**
  ------------------ -------------------------------------------------------- ---------------------------- ----------------------------- ------------------- ---------------
  Control            Normal AIN-93G diet                                      0                            253--2402 (1201 ± 807)        60.06               --
  GTPs               0.5% GTPs (Sunphenon 90D) in drinking water              60                           60--1100 (302 ± 445)          15.08               74.89
  BSp                26% BSp diet (26 g broccoli sprout/100 g AIN 93G diet)   40                           10--1800 (502 ± 750)          25.09               58.22
  Combination        0.5% Poly-E in drinking water and 26% BSp diet           60                           0--188 (74 ± 101)             3.68                93.87

^†^Prevention rate = tumor free mice number/total mice number.

^‡^TV = (length × width^2^) × 0.532.

^§^RTV = (TV on sacrificing day)/(TV on day 1 of injection), tumor volume on day 1 of injection is considered as 1.

^¶^IR on tumor growth = {1 - (mean RTV of the treatment group)/(mean RTV of the control group)} 100 \[[@B57]\].

GTP: Green tea polyphenol; BSp: Broccoli sprout; IR: Inhibition rate; RTV: Relative tumor volume; TV: Tumor volume.

###### Executive summary

**Aim** {#S0025}
-------

1.  Breast cancer is the most common cancer and the second leading cause of cancer death among women.

2.  Aberrant epigenetic events are important contributors to the pathogenesis of breast cancer and dietary botanicals with properties affecting epigenetic processes are believed to influence early cancer development leading to cancer prevention effects.

3.  Previous studies indicate that singly administered bioactive dietary components with inhibitory properties on DNA methyltransferases and histone deacetylases, such as green tea polyphenols (GTPs) and broccoli sprouts (BSp), respectively, have potent anticancer effects both *in vitro* and *in vivo*.

4.  We therefore sought to investigate potential combinatorial effects of GTPs and BSp on neutralizing epigenetic aberrations in an established breast cancer transformation system.

**Results** {#S0026}
-----------

1.  Epigallocatechin-3-gallate (EGCG) in GTPs and sulforaphane (SFN) in BSp in combination significantly inhibited initiation of breast tumorigenesis.

2.  Combined treatment with EGCG and SFN-induced cellular apoptosis and cell cycle arrest in early transformed breast cancer SHR cells.

3.  Gene expression and enzymatic activities of DNA methyltransferase 1 and histone deacetylase 1 may contribute to epigenetic regulation of key tumor-related genes leading to early breast cancer prevention and therapy.

4.  Combined treatment with EGCG and SFN leads to global changes in histone H3 acetylation and DNA methylation profiles.

5.  Combinatorial treatment with EGCG and SFN caused expression changes in tumor-related genes due to regulation of epigenetic pathways.

6.  Dietary GTPs and BSp significantly inhibited the growth of breast cancer xenografts more than any of these diets acting alone.

**Conclusion** {#S0027}
--------------

1.  Combined GTPs and BSp are highly effective in inhibiting early breast cancer development both *in vitro* and *in vivo* by, at least in part, regulating epigenetic mechanisms.

2.  This novel dietary combinatorial regimen has high translational potential for breast cancer management.
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